Center for Digestive and Liver Diseases, Inc.  © 2013  |  Privacy policy

like us

Crohn's Disease

Protocol M14-115

 

A FDA approved drug for Crohn's Disease (Humira) study evaluating higher induction vs convertional dosing to see if better outcomes and is safe.

 

A Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regiment in Subjects with Moderately to Severley Active Crohn's Disease and Evidence of Mucosal Ulceration.

 

 

 

I am interested in more information about this study.

SEND CLEAR